Arrowhead Research Corp. (NASDAQ:ARWR) Director Douglas B. Given sold 12,000 shares of the business’s stock in a transaction on Friday, October 14th. The stock was sold at an average price of $6.72, for a total value of $80,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Arrowhead Research Corp. (NASDAQ:ARWR) traded up 0.91% during mid-day trading on Tuesday, hitting $6.65. The company had a trading volume of 364,721 shares. The company’s market capitalization is $403.99 million. Arrowhead Research Corp. has a 52 week low of $3.07 and a 52 week high of $8.22. The firm’s 50 day moving average is $7.11 and its 200 day moving average is $6.18.
Arrowhead Research Corp. (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.05. Arrowhead Research Corp. had a negative return on equity of 100.50% and a negative net margin of 48,980.81%. The company earned $39.58 million during the quarter, compared to analyst estimates of $0.05 million. During the same quarter last year, the company earned ($0.27) EPS. The firm’s revenue for the quarter was down 68.0% on a year-over-year basis. On average, equities research analysts predict that Arrowhead Research Corp. will post ($1.31) EPS for the current year.
A number of research analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Arrowhead Research Corp. in a research report on Wednesday, August 17th. They set a “buy” rating and a $15.00 price target on the stock. William Blair assumed coverage on Arrowhead Research Corp. in a research report on Friday, August 19th. They set an “outperform” rating on the stock. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Arrowhead Research Corp. in a research report on Wednesday, September 7th. Finally, Piper Jaffray Cos. dropped their price target on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 10th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Arrowhead Research Corp. currently has a consensus rating of “Buy” and a consensus price target of $10.11.
A number of hedge funds and other institutional investors have recently bought and sold shares of ARWR. Quantitative Investment Management LLC bought a new position in Arrowhead Research Corp. during the second quarter worth $132,000. BlackRock Advisors LLC raised its stake in Arrowhead Research Corp. by 4.6% in the second quarter. BlackRock Advisors LLC now owns 27,943 shares of the company’s stock worth $149,000 after buying an additional 1,232 shares during the last quarter. Moors & Cabot Inc. raised its stake in Arrowhead Research Corp. by 0.6% in the second quarter. Moors & Cabot Inc. now owns 36,270 shares of the company’s stock worth $190,000 after buying an additional 200 shares during the last quarter. Nationwide Fund Advisors raised its stake in Arrowhead Research Corp. by 4.6% in the second quarter. Nationwide Fund Advisors now owns 38,161 shares of the company’s stock worth $203,000 after buying an additional 1,684 shares during the last quarter. Finally, Falcon Point Capital LLC raised its stake in Arrowhead Research Corp. by 12.5% in the second quarter. Falcon Point Capital LLC now owns 49,147 shares of the company’s stock worth $261,000 after buying an additional 5,458 shares during the last quarter. 33.97% of the stock is owned by institutional investors.
About Arrowhead Research Corp.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Receive News & Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.